TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
- The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
- With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
- Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
- The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.